JBIO

-- -- --

From March 31,2026 to June 30,2026 Exercise of stock options Issuance of common stock in connection with exercise of pre-funded warrants Issuance of common stock in the June 2026 Financing Issuance of common stock under the ATM, net of $600 issuance costs Issuance of stock under employee stock purchase plan

Common stock offered 10,000,000 shares by the company

From December 31, 2025 to March 31, 2026 Exercise of stock options

From December 31, 2024 to December 31, 2025 Exchange of Series Seed convertible preferred stock for Series A non-voting convertible preferred stock upon the closing of the reverse recapitalization Conversion of convertible notes (including accrued interest and discount) into common stock and pre-funded warrants upon the closing of the reverse recapitalization Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock and pre-funded warrants in the October 2025 Financing Issuance of common stock in the December 2025 Financing Issuance of common stock to former stockholders of Aerovate in connection with the closing of the reverse recapitalization Issuance of common stock in connection with exercise of pre-funded warrants Exercise of stock options Issuance of stock under employee stock purchase plan

Common Stock offered 3,214,286 shares by the company

From March 31, 2025 to June 30, 2025 Conversion of convertible notes (including accrued interest and discount) into common stock and pre-funded warrants upon the closing of the reverse recapitalization Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock to former stockholders of Aerovate in connection with the closing of the reverse recapitalization Issuance of common stock in connection with exercise of pre-funded warrants

1-for-35 shares of common stock, or the Reverse Stock Split; Each outstanding share of Jade Biosciences, Inc. common stock was converted into 0.6311 shares of common stock of the combined company;

From December 31, 2023 to December 31, 2024 Issuance of common stock in connection with ATM, net Issuance of common stock upon exercise of stock options Issuance of common stock under ESPP Vesting of restricted stock units

From June 30, 2024 to September 30, 2024 Issuance of common stock upon exercise of stock options

From March 31, 2024 to June 30, 2024 Vesting of restricted stock units Issuance of common stock in connection with ATM, net Issuance of common stock under ESPP Issuance of common stock upon exercise of stock options

From December 31, 2023 to March 31, 2024 Issuance of common stock upon exercise of stock options Vesting of restricted stock units

From December 31, 2022 to December 31, 2023 Issuance of common stock upon exercise of stock options Issuance of common stock under ESPP Issuance of common stock in connection with ATM, net Vesting of restricted stock units

From June 30, 2023 to September 30, 2023 Issuance of common stock upon exercise of stock options Vesting of restricted stock units

From March 31, 2023 to June 30, 2023 Issuance of common stock under ESPP Issuance of common stock upon exercise of stock options Vesting of restricted stock units Issuance of common stock in connection with ATM, net

From December 31, 2022 to March 31, 2023 Issuance of common stock upon exercise of stock options

From December 31, 2021 to December 31, 2022 Issuance of common stock under ESPP Issuance of common stock upon exercise of stock options

From June 30, 2022 to September 30, 2022 Issuance of common stock upon exercise of stock options

From March 31, 2022 to June 30, 2022 Issuance of common stock upon exercise of stock options

From June 30, 2021 to September 30, 2021 Conversion of redeemable convertible preferred stock to common stock upon initial public offering

From March 31, 2021 to June 30, 2021 Issuance of Series A redeemable convertible preferred stock at $1.893 per share, net of issuance costs of $9 Accretion of Series A redeemable convertible preferred stock to redemption value